Dendreon Corp. (DNDN) CEO Mitch Gold was on CNBC this morning to discuss the success and prospects of Provenge, a cellular immunotherapy that stimulates a patient's immune system to target and attack prostate cancer.
“We've been fighting the war on cancer for 40 years,” Gold said. However, Dendreon claims that it has extended the lives of cancer patients by an average of 4.1 months.
Gold compared an investment in Provenge to an investment in a 401k, adding that the Provenge prices are in-line with traditional chemotherapy.
This year, Gold expects facilities in LA and other cities to come online.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
